Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, 1/F, Clinical Sciences Building, New Territories, Hong Kong.
Department of Otorhinolaryngology, Head and Neck Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, New Territories, Hong Kong.
Head Neck Pathol. 2022 Sep;16(3):934-941. doi: 10.1007/s12105-022-01423-y. Epub 2022 Mar 7.
SMARCB1 (INI1)-deficient carcinoma of the sinonasal tract is a rare and distinct entity characterized by the loss of INI1 immunostain expression. These tumors are morphologically diverse, with isolated cases of yolk sac differentiation reported. We report the first case of SMARCB1-deficient sinonasal carcinoma that demonstrated co-loss of SMARCA4 immunostain, and reduced SMARCA2 and ARID1A staining, with the entire tumor showing histological and immunohistochemical evidence of yolk sac differentiation. The clinical, histological, immunohistochemical and molecular features were discussed and compared against SMARCB1-deficient sinonasal carcinomas with yolk sac differentiation and SMARCA4-deficeint sinonasal carcinomas reported in the literature. With a highly aggressive clinical course leading to mortality two months after presentation, the behavior of this tumor appears to be more comparable to that of SMARCA4-deficient sinonasal carcinomas. A comprehensive immunopanel including SMARCB1, SMARCA4, SMARCA2 and ARID1A may be advisable for assessment and prognostication of SWI/SNF-deficient tumors.
SMARCB1(INI1)缺陷型鼻腔鼻窦肿瘤是一种罕见且独特的实体,其特征是 INI1 免疫染色表达缺失。这些肿瘤形态多样,有孤立的卵黄囊分化报道。我们报告首例 SMARCB1 缺陷型鼻腔鼻窦癌,其表现为 SMARCA4 免疫染色丢失,以及 SMARCA2 和 ARID1A 染色减少,整个肿瘤具有卵黄囊分化的组织学和免疫组织化学证据。讨论了其临床、组织学、免疫组织化学和分子特征,并与文献中报道的具有卵黄囊分化的 SMARCB1 缺陷型鼻腔鼻窦癌和 SMARCA4 缺陷型鼻腔鼻窦癌进行了比较。由于临床表现高度侵袭性,导致两个月后死亡,该肿瘤的行为似乎更类似于 SMARCA4 缺陷型鼻腔鼻窦癌。包括 SMARCB1、SMARCA4、SMARCA2 和 ARID1A 的全面免疫组化分析可能有助于评估和预测 SWI/SNF 缺陷型肿瘤。